BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.

BioNTech SE (NASDAQ:BNTX) saw its shares rise 2.45% in pre-market trading Monday following a strong second-quarter report ...

BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...

BioNTech SE BNTX +3.21% Get Free Report reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

Analysts estimate that BioNTech will report an earnings per share (EPS) of $-1.31. The market awaits BioNTech's announcement, ...

Pfizer (PFE) and BioNTech (BNTX) lose bid to appeal a High Court ruling that issued Moderna (MRNA) a COVID-19 vaccine patent ...

On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.

Investors in BioNTech SE (Symbol: BNTX) saw new options begin trading today, for the June 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is ...

Investors in BioNTech SE (Symbol: BNTX) saw new options begin trading this week, for the April 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BNTX ...

BioNTech (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about ...